Thrombocytopenia: Etiological Factors, Diagnostic Evaluation, and Clinical Treatment Strategies

Thrombocytes represent essential circulating cellular elements orchestrating primary hemostasis and vascular endothelial repair:

• Reference physiological range – 150,000 to 450,000 platelets per microliter (150–450 × 10⁹/L).
• Clinical severity staging – mild (100,000–150,000/µL), moderate (50,000–100,000/µL), severe (20,000–50,000/µL), and critical life-threatening nadir (<20,000/µL, bearing high risks of spontaneous organ hemorrhage).
• Exclusion of pseudothrombocytopenia – initial clinical protocol dictates ruling out in vitro EDTA-dependent agglutination via repeat complete blood count using sodium citrate or heparin anticoagulation and direct microscopic examination of the peripheral blood smear.

Platelet depletion originates from two broad pathophysiological classifications:

• Primary immune thrombocytopenia (ITP) – an autoimmune condition characterized by pathogenic IgG autoantibodies directed against platelet surface glycoproteins (GPIIb/IIIa and GPIb/IX), mediating splenic macrophage phagocytosis and suppressing megakaryocyte thrombopoiesis.
• Secondary thrombocytopenia – driven by underlying systemic pathologies: chronic viral infections (hepatitis C, HIV, EBV, CMV), gastric Helicobacter pylori colonization, systemic lupus erythematosus (SLE), and chronic lymphocytic leukemia (CLL).
• Pharmacological and toxic triggers – drug-induced thrombocytopenia, prominently heparin-induced thrombocytopenia (HIT type II), cytotoxic chemotherapeutics, anticonvulsants, and direct ethanol marrow suppression.
• Marrow infiltration and hypersplenism – bone marrow aplasia, myelodysplastic syndromes, megaloblastic cobalamin/folate deficiency, and splenic pooling secondary to portal hypertension in liver cirrhosis.

Hemorrhagic phenotype is tightly coupled to absolute circulating platelet counts:

• Counts > 50,000/µL – patients remain largely asymptomatic with preserved hemostatic reserve; abnormal bleeding arises only following major surgical interventions or severe trauma.
• Counts 20,000–50,000/µL – manifestations of minor mucocutaneous purpura: easy bruising, dependent petechial showers, prolonged bleeding after minor dental procedures or lacerations.
• Counts < 20,000/µL – marked risk of spontaneous hemorrhage: mucosal oral wet purpura (blood blisters on buccal mucosa), persistent epistaxis, gross hematuria, and menorrhagia.
• Counts < 10,000/µL – medical emergency threshold; exponential risk of life-threatening intracranial hemorrhage or catastrophic gastrointestinal bleeding.

Modern clinical hematology employs evidence-based targeted regimens tailored to etiology:

• First-line therapy for ITP – oral corticosteroids (prednisone 1 mg/kg daily or high-dose pulsed dexamethasone 40 mg/day for 4 days) dampening macrophage-mediated clearance and autoantibody production. High-dose intravenous immunoglobulin (IVIG 1 g/kg) provides rapid Fc-receptor blockade in acute hemorrhagic presentations.
• Second-line therapeutics – thrombopoietin receptor agonists (TPO-RAs: romiplostim, eltrombopag, avatrombopag) stimulating megakaryocyte thrombopoiesis; rituximab (anti-CD20 monoclonal antibody depleting autoreactive B cells); and laparoscopic splenectomy removing the primary site of clearance.
• Life-threatening hemorrhage protocol – emergency co-administration of platelet concentrate transfusions, high-dose IVIG, intravenous methylprednisolone, and antifibrinolytic tranexamic acid.
• Secondary management – targeted therapy of primary driver: eradication of Helicobacter pylori, direct-acting antivirals for HCV, or immediate withdrawal of suspected offending medications.